Zobrazeno 1 - 10
of 236
pro vyhledávání: '"Marco, Montillo"'
Autor:
Anna Maria Frustaci, Marco Montillo, Davide Rossi, Pier Luigi Zinzani, Marina Motta, Gianluca Gaidano, Giulia Quaresmini, Lydia Scarfò, Daniela Pietrasanta, Marta Coscia, Marina Deodato, Giulia Zamprogna, Roberto Cairoli, Georg Stüssi, Emanuele Zucca, Stefano Pileri, Thorsten Zenz, Alessandra Tedeschi
Publikováno v:
HemaSphere, Vol 7, p e6990566 (2023)
Externí odkaz:
https://doaj.org/article/d76720e6bf5245369b7701323789dc2d
Autor:
Arnon Kater, Rosemary Harrup, Thomas J Kipps, Barbara Eichhorst, Carolyn J Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Maria Thadani-Mulero, Marcus Lefebure, Yanwen Jiang, Rosemary Millen, Michelle Boyer, John F Seymour
Publikováno v:
HemaSphere, Vol 7, p e492813f (2023)
Externí odkaz:
https://doaj.org/article/40a72c8b5e324b6bb0a316c864da72a7
Autor:
Anna Maria Frustaci, Giovanni Del Poeta, Andrea Visentin, Paolo Sportoletti, Alberto Fresa, Candida Vitale, Roberta Murru, Annalisa Chiarenza, Alessandro Sanna, Francesca Romana Mauro, Gianluigi Reda, Massimo Gentile, Marzia Varettoni, Claudia Baratè, Chiara Borella, Antonino Greco, Marina Deodato, Giulia Zamprogna, Roberta Laureana, Alessandra Cipiciani, Andrea Galitzia, Angelo Curto Pelle, Francesca Morelli, Lucio Malvisi, Marta Coscia, Luca Laurenti, Livio Trentin, Marco Montillo, Roberto Cairoli, Alessandra Tedeschi
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
Background: The question of which parameters may be informative on venetoclax outcome in chronic lymphocytic leukemia (CLL) is still unclear. Furthermore, the choice to treat with venetoclax can be challenging in patients with baseline characteristic
Externí odkaz:
https://doaj.org/article/dbe82a2f5bd44711a4eb104c37135499
Autor:
Matthew Kaufman, Xiao-Jie Yan, Wentian Li, Emanuela M. Ghia, Anton W. Langerak, Laura Z. Rassenti, Chrysoula Belessi, Neil E. Kay, Frederic Davi, John C. Byrd, Sarka Pospisilova, Jennifer R. Brown, Mark Catherwood, Zadie Davis, David Oscier, Marco Montillo, Livio Trentin, Richard Rosenquist, Paolo Ghia, Jacqueline C. Barrientos, Jonathan E. Kolitz, Steven L. Allen, Kanti R. Rai, Kostas Stamatopoulos, Thomas J. Kipps, Donna Neuberg, Nicholas Chiorazzi
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Patients with CLL with mutated IGHV genes (M-CLL) have better outcomes than patients with unmutated IGHVs (U-CLL). Since U-CLL usually express immunoglobulins (IGs) that are more autoreactive and more effectively transduce signals to leukemic B cells
Externí odkaz:
https://doaj.org/article/c619ded3a3974ed5becc2e624f138274
Autor:
Anna Maria Frustaci, Marina Deodato, Giulia Zamprogna, Roberto Cairoli, Marco Montillo, Alessandra Tedeschi
Publikováno v:
Cancers, Vol 15, Iss 5, p 1504 (2023)
Ibrutinib revolutionized the CLL treatment approach and prognosis demonstrating its efficacy and safety even at extended follow-up. During the last few years, several next-generation inhibitors have been developed to overcome the occurrence of toxici
Externí odkaz:
https://doaj.org/article/46351d29170d4f65a119df94cea9f42a
Autor:
Marco Montillo, Árpád Illés, Tadeusz Robak, Alexander S. Pristupa, Malgorzata Wach, Miklós Egyed, Julio Delgado, Wojciech Jurczak, Franck Morschhauser, Anna Schuh, Herbert Eradat, Sanatan Shreay, Jacqueline C. Barrientos, Andrew D. Zelenetz
Publikováno v:
Health and Quality of Life Outcomes, Vol 17, Iss 1, Pp 1-11 (2019)
Abstract Background In a phase 3 randomized, double-blind, placebo-controlled trial, treatment with idelalisib, a phosphoinositol-3 kinase δ inhibitor, + bendamustine/rituximab improved progression-free survival (PFS) and overall survival (OS) in ad
Externí odkaz:
https://doaj.org/article/a4213c5a007349f1aa21693a3409fcfd
Autor:
Michael Steurer, Marco Montillo, Lydia Scarfò, Francesca R. Mauro, Johannes Andel, Sophie Wildner, Livio Trentin, Ann Janssens, Sonja Burgstaller, Anna Frömming, Thomas Dümmler, Kai Riecke, Matthias Baumann, Diana Beyer, Stéphanie Vauléon, Paolo Ghia, Robin Foà, Federico Caligaris-Cappio, Marco Gobbi
Publikováno v:
Haematologica, Vol 104, Iss 10 (2019)
Olaptesed pegol (NOX-A12) is a pegylated structured L-oligoribonucleotide that binds and neutralizes CXCL12, a chemokine tightly regulating the life cycle of chronic lymphocytic leukemia cells. The resulting inhibition of CXCR4 and CXCR7 signaling re
Externí odkaz:
https://doaj.org/article/e87d8b780fc74f3e8d8ce9bfbe956c1b
Autor:
Ulrich Jäger, Hagop Youssoufian, David T. Weaver, Stephanie Lustgarten, Julio Delgado, Paolo Ghia, Stephan Stilgenbauer, Constantine S. Tam, Zsolt Nagy, Nicole Lamanna, James Essell, Carol Moreno, Marco Montillo, Peter Hillmen, Bryone J. Kuss, Matthew S. Davids
Figure S2C displays probability of progression-free survival over time in subgroups of patients with and without bulky disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::152c7ea446cf144ad2e43d438a8f2897
https://doi.org/10.1158/1078-0432.22480017.v1
https://doi.org/10.1158/1078-0432.22480017.v1
Autor:
Ulrich Jäger, Hagop Youssoufian, David T. Weaver, Stephanie Lustgarten, Julio Delgado, Paolo Ghia, Stephan Stilgenbauer, Constantine S. Tam, Zsolt Nagy, Nicole Lamanna, James Essell, Carol Moreno, Marco Montillo, Peter Hillmen, Bryone J. Kuss, Matthew S. Davids
Purpose:In the phase III DUO trial, duvelisib, an oral dual PI3K-δ,γ inhibitor, demonstrated significantly improved efficacy versus ofatumumab [median (m) progression-free survival (PFS), 13.3 vs. 9.9 months (HR, 0.52; P < 0.0001); overall response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0496bb2e62d2e2c36e2292b9adc9d9a1
https://doi.org/10.1158/1078-0432.c.6530352
https://doi.org/10.1158/1078-0432.c.6530352
Autor:
Ulrich Jäger, Hagop Youssoufian, David T. Weaver, Stephanie Lustgarten, Julio Delgado, Paolo Ghia, Stephan Stilgenbauer, Constantine S. Tam, Zsolt Nagy, Nicole Lamanna, James Essell, Carol Moreno, Marco Montillo, Peter Hillmen, Bryone J. Kuss, Matthew S. Davids
Supplemental Figure Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57960b910570bf6d94cb6e2cefec079a
https://doi.org/10.1158/1078-0432.22480029
https://doi.org/10.1158/1078-0432.22480029